BIONANO GENOMICS INC (BNGO)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$1.20-3.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Bionano aims for $30-$33 million revenue in 2026. Q1 revenue was $6.7 million. The company is improving after recent beats. Revenue growth targets show progress but profitability remains a challenge.
The company is still losing money with negative operating income. CEO and CMO departures hurt confidence. Revenue growth is slow and may miss targets.
The market expects about 32% revenue growth in 2026. Our fair value is near $7.07, reflecting cautious optimism. We see risk from ongoing losses and leadership changes.
Breaks if: Operating loss worsens or stays below -$7.9 million
Breaks if: Q2 2026 revenue falls below $7.5 million
Full year 2026 revenue falls below $30 million
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
BNGO represents a speculative growth investment with a focus on expanding its scientific leadership and achieving revenue targets. The current thesis state is cautious, as recent financial performance has been mixed, and the company is navigating a high-risk environment.
The market appears to have priced in a low level of fragility, indicating that BNGO is seen as relatively stable compared to its peers. However, there is an expectations gap, suggesting that the market may not fully anticipate the challenges ahead in execution and guidance.
Management is on track to meet its revenue goals for 2026, but the company remains loss-making. The recent appointment of a new Chief Scientific Officer indicates a focus on innovation, though it is too early to assess its impact on financial performance.
The long-term thesis hinges on management's ability to maintain or improve revenue guidance and the performance of sector bellwethers. Additionally, macroeconomic factors, such as employment trends, could significantly influence BNGO's performance.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company aims for $31-$33 million in revenue. This supports the thesis. However, the latest earnings report missed expectations. This weakens the read on the company.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, BNGO's prospects will depend on effective execution and favorable sector conditions. Not investment advice.